This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
cdk4-6
CDK4/6
Cyclin D-dependent kinases; phosphorylate Rb to release E2F transcription factors → G1→S cell cycle entry. Amplified or activated in HR+ breast cancer, melanoma (CDKN2A loss), and others. Palbociclib, ribociclib, abemaciclib block CDK4/6 → Rb hypophosphorylation → G1 arrest.
Entry Metadata
| Field | Value |
|---|---|
| ID | cdk4-6 |
| Name | CDK4/6 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov. 2016;6(4):353-367. · PubMed 26658964
- Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-1936. · PubMed 27959613
- Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704-707. · PubMed 8259214